Is Boston Scientific (BSX) overvalued or fairly valued?

MarketChacha shows Boston Scientific's valuation in context — a forward P/E of about 11.5, a price-to-book of about 2.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Boston Scientific (BSX)?

Boston Scientific last traded at $42.72 (-1.1% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Boston Scientific

BSX · NYSE · Healthcare · United States

$42.72-1.1%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 5:38 PM

Snapshot

TickerBSX

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees59,000

HeadquartersMarlborough, United States

Market cap$63.5B

P/B2.5

Volume4.43M

Websitewww.bostonscientific.com

Filings tracked0

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.2%
Institutions93.9%
Public & other5.9%

2,336 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.8.87%
Vanguard Capital Management LLC6.49%
FMR, LLC4.99%
State Street Corporation4.57%
JPMORGAN CHASE & CO2.24%
Geode Capital Management, LLC2.24%
Primecap Management Company2.19%
Vanguard Portfolio Management LLC2.00%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $5.4B · EPS 0.84

Est. earnings growth +11.7%

Next fiscal year

Rev $23.3B · EPS 3.71

Est. earnings growth +10.5%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$42.2052-wk range$109.50

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about BSX

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.